Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD) and its large proprietary library of medicinal plants, including plants with novel psychedelic and other psychoactive effects SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Karen Brunke, PhD, the company's Executive Vice President of Corporate and Business Development, will be attending BIO 2022, taking place at the San Diego Convention Center from June 13 - 16, 2022. Dr. Brunke will be participating in one-on-one meetings throughout the conference.

Jaguar Health to Participate in BIO International Convention (BIO 2022)

Drug Discovery Collaboration Will Leverage the Botanical Drug Development Expertise of Both Companies SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Health Corp. (NEO:FH) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States. The goal of the collaboration is to extend the botanical drug development skillsets of both companies in order to develop pharmaceutical-grade, standardized drug candidates and partner with a potential future licensee regarding the development and commercialization of these novel plant-based drugs for indications such as attention-deficit/hyperactivity disorder (ADHD) and social anxiety disorder.

Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2022 / Jaguar Health (NASDAQ:JAGX) today announced that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on expanding crofelemer access in Europe, has submitted an Orphan Drug Designation (ODD) application for crofelemer for a rare congenital diarrheal disorder (CDD) condition called microvillus inclusion disease (MVID) to the European Medicines Agency (EMA). The submission is the first step of the process; the review by the EMA's Committee for Orphan Medicinal Products (COMP) will start after the validation of the submission.

Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the presentation of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, as a potential anti-diarrheal to mitigate the consequences of microvillus inclusion disease (MVID), a severe congenital diarrheal disorder (CDD), at Digestive Disease Week ® (DDW 2022), which took place May 21-24, 2022 in San Diego, CA. "Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea," said Pravin Chaturvedi, PhD, Jaguar Health's Chief Scientific Officer and Chair of the company's Scientific Advisory Board.

Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Diarrheal Disorder at 2022 Digestive Disease Week

Catalyst Biosciences

Cybin

Kala Pharmaceuticals

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch Under $1

"Canine Cancer: Take C.H.A.R.G.E." (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical Records Initial Data from Gallup Poll of More Than 3,500 Dog Owners Suggest Nearly Five-Fold Greater Incidence of Canine Cancer Than Human Cancer; More Than 80 Percent of Respondents Believe a Registry is Needed to Help Dogs with Cancer Take C.H.A.R.G.E.

Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index

Click here to RSVP for this in-person, outdoor event Human and doggy swag will be available*, and the event will feature presentations by well-known veterinary cancer specialists, including Dr. Sue Cancer Vet, and performances by Broadway stars This is a special event for ALL interested parties - dog owners, veterinarians, veterinary oncology specialists, investors, the media, and anyone who is concerned about addressing and managing cancer in our four-legged best friends SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) is hosting a special media event and performance in New York City on Monday, May 23rd, 2022 from 12:30 to 2:30 PM Eastern to celebrate the launch of the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) initiative - the first-ever U.S. Canine Cancer Registry and Cancer Care index - because protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location.

Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!

SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company.

TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health

This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically Appropriate for Them SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). "Telehealth facilitates faster and more expansive patient access to much needed medical care.

Jaguar Health Announces Launch of Mytesi Telehealth Program

Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Conte – Founder, President and Chief Executive Officer Carol Lizak – Chief Financial Officer Ian H. Wendt – Chief Commercial Officer Peter Hodge – Senior Director of Investor Relations, Business Development and Special Events Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that the -- that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2022 Results - Earnings Call Transcript

Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021 Core initiatives: OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion of enrollment 1H 2023 Targeted completion in 2022 & 2023 of investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders, supporting the potential for expanded patient access through programs in Europe in 2023 Ongoing launch of Canalevia®-CA1, which is now commercially available for treatment of chemotherapy-induced diarrhea (CID) in dogs REMINDER: Jaguar to host investor webcast Tuesday, May 10th at 8:30 a.m. Eastern regarding first quarter 2022 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated first quarter 2022 financial results.

Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, May 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDA SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has completed filing of the final regulatory section with the U.S. Food and Drug Administration's (FDA) Center for Veterinary Medicine (CVM) to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (EID) in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia®-CA1 for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available from multiple leading veterinary distributors in the U.S. Canalevia-CA1 received conditional approval from the FDA on December 21, 2021. "We are very excited that Canalevia-CA1 is now available to veterinarians across the country," said Chip Whitlow, Sales & Marketing Director of the company's Animal Health Commercial Portfolio.

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida on Thursday, April 21, 2022, at 11:00 AM Eastern. There is also the opportunity to meet Jaguar management at the company's breakout session scheduled for 10:00 AM Eastern the same day.

Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary oncologists can click here to register for the dinner and tableside discussion SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is hosting a dinner and tableside discussion for U.S. veterinary oncologists in Puerto Vallarta, Mexico from 5:30 PM - 10:00 PM on Tuesday, April 12, 2022, the final day of the Veterinary Cancer Society (VCS) Mid-Year Conference. This exclusive dinner experience will feature a private chef, entertainment, and a tableside discussion on treatment therapies for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico

Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with anticipated key milestones in the next 12-15 months. SAN FRANCISCO, CA / ACCESSWIRE / April 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer.

Here's Why Jaguar Health Shares Are Rising

BitNile Holdings

Tonix Pharmaceuticals Hld

Check these 3 penny stocks out for your watchlist this month The post Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1

Ambev

Vinco Ventures

Which penny stocks are you watching in April? The post Best Penny Stocks to Buy as March Comes to an End?

Best Penny Stocks to Buy as March Comes to an End? 3 to Check Out

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer in the Middle East. Per.

Here's Why Jaguar Health Shares Are Popping Off

Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today. The post Why Is Jaguar Health (JAGX) Stock Up Today?

Why Is Jaguar Health (JAGX) Stock Up Today?

Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human indications of crofelemer approved in the U.S., including future target indications SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company has entered an agreement (the "Agreement") with Quadri Pharmaceuticals Store LLC (Quadri Pharma) that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates (UAE), and Oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the U.S. for HIV-related diarrhea, and cancer therapy-related diarrhea, for which crofelemer is currently in a pivotal Phase 3 clinical trial. In addition, the Agreement grants Quadri Pharma exclusive rights to distribute crofelemer in these countries in the immediate future under Named Patient Programs.

Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2021 Results - Earnings Call Transcript

News for Jaguar Health Stock (JAGX)